As the FDA cracks down on compounded GLP-1 drugs like semaglutide and tirzepatide, the market for GLP-1 supplements is taking ...

The prospect of a pill rather than an injection is obviously appealing to some people, but will fear of needles be enough to ...

Half of the participants took a semaglutide tablet daily and half took a placebo. Participants continued their assigned regimen for an average of just under four years. By the end of the trial ...

Eli Lilly surged during Thursday's trading session after promising test results came out of the pharmaceutical company's ...

INDIANAPOLIS – The way people are accessing GLP-1 medications Semaglutide and Tirzepatide is going to become very limited after the drugs were taken off the FDA’s shortage list. Hundreds of ...

Semaglutide is the active ingredient in Wegovy It is also the main component of Ozempic Semaglutide is known to increase the risk of hair loss Semaglutide, the main ingredient in Ozempic and ...

The cardiovascular safety of oral semaglutide, a glucagon-like peptide 1 receptor agonist, has been established in persons with type 2 diabetes and high cardiovascular risk. An assessment of the ...

CHICAGO -- Semaglutide further solidified its efficacy ... Participants were told to take their assigned tablet in the morning, with a little water and no food or other medications until at ...

The use of semaglutide in patients with diabetes was associated with a significantly increased risk for nonarteritic anterior ischemic optic neuropathy (NAION) compared with those taking drugs for ...

CHICAGO — Semaglutide, a glucagon-like peptide (GLP-1) receptor agonist, has shown convincing benefits in yet another population: patients with peripheral arterial disease (PAD). In the STRIDE ...

The large-scale study focused on use of semaglutide and non-GLP-1 RAs. An increased risk for nonarteritic anterior ischemic optic neuropathy with semaglutide was seen at 2, 3 and 4 years from the ...